Clinical trial
Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS
NCT00467610 · Rush University Medical Center, Other · Terminated
Key facts
| NCT number | NCT00467610 |
|---|---|
| Title | Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS |
| Official title | A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome |
| Lead sponsor | Rush University Medical Center, Other |
| Collaborators | H. Lundbeck A/S Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Panhematin |
| Enrollment | 6 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Apr 30, 2007 |
| Last update posted | Oct 24, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: